-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TSHA-102 in Rett Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TSHA-102 in Rett Syndrome report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TSHA-102 in Rett Syndrome Drug Details: TSHA-102 (TGTX-104) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ASP-8374 in Recurrent Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ASP-8374 in Recurrent Glioblastoma Multiforme (GBM) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ASP-8374 in Recurrent Glioblastoma Multiforme (GBM) Drug Details: ASP-8374...
-
Product Insights
NewJuvenile Macular Degeneration (Stargardt Disease) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Juvenile Macular Degeneration Clinical Trial Report Overview A total of 59 Juvenile Macular Degeneration clinical trials were conducted as of April 2024. The Juvenile Macular Degeneration clinical trial report provides a comprehensive understanding of the Juvenile Macular Degeneration clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EXS-617 in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EXS-617 in Pancreatic Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. EXS-617 in Pancreatic Cancer Drug Details: EXS-617 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zolbetuximab in Metastatic Adenocarcinoma of The Pancreas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zolbetuximab in Metastatic Adenocarcinoma of The Pancreas report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zolbetuximab in Metastatic Adenocarcinoma of The Pancreas Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AMG-305 in Uterine Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AMG-305 in Uterine Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AMG-305 in Uterine Cancer Drug Details: Monoclonal antibody is under development...
-
Sector Analysis
NewFuture of Pharma – Looking Ahead to 2024
This report provides a summary of the near and long-term future of the pharmaceutical industry from the standpoint of drug development. It provides a high-level analysis of key trends and movements within the industry via regulatory, clinical, and market-based analysis, allowing you to discern the large-scale changes and how best to pivot and prioritize them within your sectors.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Enfortumab Vedotin in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Enfortumab Vedotin in Gastric Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Enfortumab Vedotin in Gastric Cancer Drug Details: Enfortumab vedotin (Padcev)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Enfortumab Vedotin in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Enfortumab Vedotin in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Enfortumab Vedotin in Non-Small Cell Lung Cancer Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Enfortumab Vedotin in Esophageal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Enfortumab Vedotin in Esophageal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Enfortumab Vedotin in Esophageal Cancer Drug Details: Enfortumab vedotin (Padcev)...